{
  "nodes": [
    {
      "id": "N1",
      "label": "Step 1",
      "customData": {
        "node_id": "A",
        "node_step_index": 0,
        "content": "58-year-old Chinese male presented for a physical examination on 20 April 2020. Patient was asymptomatic, with no cough, sputum, hemoptysis, chest pain, or dyspnea. No history of diabetes, hypertension, or family history of cancer. Smoking history of over 7 years, with an average of 20\u201340 cigarettes per day, and had abstained from smoking for nearly 30 years.",
        "clinical_data": {
          "social_history": [
            {
              "category": "smoking",
              "status": "past",
              "description": "History of over 7 years, with an average of 20\u201340 cigarettes per day, and had abstained from smoking for nearly 30 years."
            }
          ],
          "HPI": [
            {
              "summary": "Patient was asymptomatic, with no cough, sputum, hemoptysis, chest pain, or dyspnea.",
              "onset": "2020-04-20",
              "progression": "unknown",
              "associated_symptoms": [],
              "alleviating_factors": [],
              "exacerbating_factors": []
            }
          ]
        }
      }
    },
    {
      "id": "N2",
      "label": "Step 2",
      "customData": {
        "node_id": "B",
        "node_step_index": 1,
        "content": "Chest CT revealed a 4.0 cm x 3.4 cm mass in the inferior lobe of the right lung, along with swollen and fused lymph nodes in the hilum and mediastinum. CT-guided lung biopsy revealed lung adenocarcinoma. Immunohistochemical staining positive for Napsin A and thyroid transcription factor 1 (TTF1). Diagnosis of stage IIIA (T2aN2M0) lung adenocarcinoma confirmed on 2 May 2020.",
        "clinical_data": {
          "imaging": [
            {
              "type": "Mass",
              "body_part": "Lung",
              "modality": "CT",
              "finding": "4.0 cm x 3.4 cm mass in the inferior lobe of the right lung",
              "impression": "Mass in the inferior lobe of the right lung",
              "date": null
            },
            {
              "type": "Lymph node",
              "body_part": "Hilar region",
              "modality": "CT",
              "finding": "Swollen and fused lymph nodes in the hilum and mediastinum",
              "impression": "Swollen and fused lymph nodes in the hilum and mediastinum",
              "date": null
            }
          ],
          "procedures": [
            {
              "name": "Lung Biopsy",
              "approach": "percutaneous",
              "date": null,
              "location": "Lung",
              "performed_by": null,
              "outcome": null
            }
          ],
          "diagnoses": [
            {
              "code": "C34.9",
              "label": "Lung Adenocarcinoma",
              "status": "active",
              "onset_date": "2020-05-02"
            }
          ],
          "labs": [
            {
              "test": "Napsin A",
              "value": "positive",
              "unit": null,
              "flag": "positive",
              "reference_range": null,
              "timestamp": null
            },
            {
              "test": "Thyroid Transcription Factor 1",
              "value": "positive",
              "unit": null,
              "flag": "positive",
              "reference_range": null,
              "timestamp": null
            }
          ]
        }
      }
    },
    {
      "id": "N3",
      "label": "Step 3",
      "customData": {
        "node_id": "C",
        "node_step_index": 2,
        "content": "Next-generation sequencing (NGS) from tumor tissue via lung puncture identified ELMOD3-ALK (E8: A20) fusion (41.23% abundance) and EML4-ALK (E13: A20) double-ALK fusion (68.21% abundance). ELMOD3-ALK fusion involved a break and rearrangement of exon 8 of the ELMOD3 gene and exon 20 of the ALK gene. ALK fusion confirmed by IHC staining with Ventana D5F3 clone.",
        "clinical_data": {
          "imaging": [
            {
              "type": "Lung puncture",
              "body_part": "Lung",
              "modality": "other",
              "finding": "ELMOD3-ALK (E8: A20) fusion (41.23% abundance) and EML4-ALK (E13: A20) double-ALK fusion (68.21% abundance)",
              "impression": "ALK fusion confirmed by IHC staining with Ventana D5F3 clone."
            }
          ],
          "diagnoses": [
            {
              "code": "C4024",
              "label": "ALK positive cancer",
              "status": "active"
            }
          ]
        }
      }
    },
    {
      "id": "N4",
      "label": "Step 4",
      "customData": {
        "node_id": "D",
        "node_step_index": 3,
        "content": "Patient started on alectinib 600 mg twice daily on 20 May 2020 for potentially resectable NSCLC with ALK rearrangement. After more than 4 months of alectinib therapy, chest CT scan showed shrinkage of the primary tumor with a 1.1 cm x 0.6 cm nodule in the inferior lobe of the right lung without lymph node enlargement. CEA, NSE, and CA19-9 levels dropped sharply compared to initial levels. Partial response (PR) to alectinib therapy per RECIST 1.1 criteria.",
        "clinical_data": {
          "medications": [
            {
              "drug": "alectinib",
              "dosage": "600 mg",
              "frequency": "twice daily",
              "start_date": "2020-05-20",
              "end_date": null,
              "indication": "Non-Small Cell Lung Carcinoma"
            }
          ],
          "imaging": [
            {
              "type": "CT Chest",
              "body_part": "Lung",
              "modality": "CT",
              "finding": "shrinkage of the primary tumor with a 1.1 cm x 0.6 cm nodule in the inferior lobe of the right lung without lymph node enlargement",
              "date": null
            }
          ],
          "labs": [
            {
              "test": "Carcinoembryonic Antigen Measurement",
              "value": "dropped sharply compared to initial levels",
              "unit": null,
              "flag": null,
              "reference_range": null,
              "timestamp": null
            },
            {
              "test": "Neuron-Specific Enolase Measurement",
              "value": "dropped sharply compared to initial levels",
              "unit": null,
              "flag": null,
              "reference_range": null,
              "timestamp": null
            },
            {
              "test": "CA 19-9 antigen measurement",
              "value": "dropped sharply compared to initial levels",
              "unit": null,
              "flag": null,
              "reference_range": null,
              "timestamp": null
            }
          ],
          "diagnoses": [
            {
              "code": "Non-Small Cell Lung Carcinoma",
              "label": "Non-Small Cell Lung Carcinoma",
              "status": "active",
              "onset_date": null
            }
          ]
        }
      }
    }
  ],
  "edges": [
    {
      "from": "N1",
      "to": "N2",
      "data": {
        "edge_id": "A_to_B",
        "branch_flag": true,
        "content": "Transition from asymptomatic presentation to lung mass detection and diagnosis of stage IIIA lung adenocarcinoma.",
        "transition_event": {
          "trigger_type": "imaging",
          "trigger_entities": [
            "C0206208"
          ],
          "change_type": "progression",
          "target_domain": "diagnosis",
          "timestamp": "2020-05-02"
        }
      }
    },
    {
      "from": "N2",
      "to": "N3",
      "data": {
        "edge_id": "B_to_C",
        "branch_flag": true,
        "content": "Identification of ELMOD3-ALK and EML4-ALK fusions via next-generation sequencing (NGS) from tumor tissue.",
        "transition_event": {
          "trigger_type": "lab_change",
          "trigger_entities": [],
          "change_type": "addition",
          "target_domain": "diagnosis"
        }
      }
    },
    {
      "from": "N3",
      "to": "N4",
      "data": {
        "edge_id": "C_to_D",
        "branch_flag": true,
        "content": "Initiation of alectinib therapy and subsequent partial response (PR) based on imaging and tumor marker reduction.",
        "transition_event": {
          "trigger_type": "medication_change",
          "trigger_entities": [
            "C1613779"
          ],
          "change_type": "addition",
          "target_domain": "medication",
          "timestamp": "2020-05-20"
        }
      }
    }
  ]
}